Procedure for setting control for the turnover of new, potentially hazardous psychoactive substances. Detection of metabolites of a new APINAC psychoactive compound in rat urine by gas and liquid chromatography with mass spectrometry detection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The appearance of a new APINAC compound (AKB-57, ACBL(N)-018, adamantan-1-yl-1-pentyl-1H-indazol-3-carboxylate) in the Russian market of psychoactive drugs led to the need in setting measures of state control over its turnover and in solving the problem of categorizing this compound as a potentially hazardous psychoactive substance. To establish these control measures, it was necessary to determine the appropriate chromatographic–mass spectrometric characteristics and to search for its metabolites for their subsequent automated detection. The structure of an APINAC molecule has significant similarity with the molecules of other synthetic cannabinoids. In this paper, primary information on the metabolism of APINAC in the body of rats is presented. A number of putative metabolites, which are the products of hydrolysis of the initial structure and additional monohydroxylation of these products, carbonylation and carboxylation of the lateral N-pentyl chain of indazole-containing metabolites, were detected in rat urine by liquid chromatography–mass spectrometry in the mode of measurement of exact masses and gas chromatography–mass spectrometry. It was found that the formation of glucuronides is characteristic for 1-adamantol and its monohydroxylated metabolite and for the indazole-containing product of hydrolysis of APINAC. The presented mass spectra and retention characteristics of the detected metabolites can help in the detection of these (or similar) compounds in human urine.

About the authors

S. A. Savchuk

Sechenov First Moscow State Medical University; Russian Center of Forensic Expertise

Author for correspondence.
Email: serg-savchuk@yandex.ru
Russian Federation, Moscow, 119991; Moscow, 125284

S. A. Appolonova

Sechenov First Moscow State Medical University

Email: serg-savchuk@yandex.ru
Russian Federation, Moscow, 119991

O. M. Kogdas’

21st Department of the General Administration for Drug Control

Email: serg-savchuk@yandex.ru
Russian Federation, Moscow, 119049

V. N. Unizhaev

21st Department of the General Administration for Drug Control

Email: serg-savchuk@yandex.ru
Russian Federation, Moscow, 119049

O. S. Gorina

Bureau of Forensic Expertise

Email: serg-savchuk@yandex.ru
Russian Federation, Saratov, 410071

L. N. Rizvanova

Nizhnevartovsk Psychoneurological Hospital

Email: serg-savchuk@yandex.ru
Russian Federation, Nizhnevartovsk, 628615

N. V. Samyshkina

Novy Urengoy Psychoneurological Dispensary

Email: serg-savchuk@yandex.ru
Russian Federation, Novy Urengoy, 629305

K. M. Shestakova

Sechenov First Moscow State Medical University

Email: serg-savchuk@yandex.ru
Russian Federation, Moscow, 119991


Copyright (c) 2017 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies